FAM172A (Family With Sequence Similarity 172 Member A) is a relatively uncharacterized protein that has garnered interest in neurodegeneration research due to its genetic associations with [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). While the precise biological functions of FAM172A remain under investigation, studies suggest it may play roles in cellular metabolism, protein quality control, and neuronal survival.
Structure and Evolution
Protein Architecture
FAM172A is a relatively small protein of approximately 326 amino acids with the following structural features:
...
FAM172A Protein (Family With Sequence Similarity 172 Member A)
FAM172A (Family With Sequence Similarity 172 Member A) is a relatively uncharacterized protein that has garnered interest in neurodegeneration research due to its genetic associations with [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). While the precise biological functions of FAM172A remain under investigation, studies suggest it may play roles in cellular metabolism, protein quality control, and neuronal survival.
Structure and Evolution
Protein Architecture
FAM172A is a relatively small protein of approximately 326 amino acids with the following structural features:
N-terminal domain: Contains predicted coiled-coil regions that may mediate protein-protein interactions
Central region: Low-complexity sequences with potential regulatory functions
C-terminal domain: Highly conserved across species, suggesting functional importance
The protein is conserved from mammals to fish, indicating an evolutionarily important function.
Expression Patterns
FAM172A demonstrates broad tissue expression with notable highlights in:
Central nervous system: Expressed in various brain regions including the [hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), and cerebellum
Peripheral tissues: Highest expression in testis, with moderate levels in liver, kidney, and heart
Cellular localization: Primarily cytoplasmic, with some nuclear localization reported
Role in Neurodegeneration
Alzheimer's Disease
FAM172A has been implicated in Alzheimer's disease through multiple lines of evidence:
Genetic associations: Genome-wide association studies (GWAS) have identified FAM172A variants associated with late-onset AD risk
[Amyloid-beta](/proteins/amyloid-beta) metabolism: Preliminary studies suggest FAM172A may interact with proteins involved in [amyloid precursor protein](/genes/app) (APP) processing
[Tau](/proteins/tau) pathology: Some evidence links FAM172A to tau phosphorylation pathways
Parkinson's Disease
In Parkinson's disease research, FAM172A has been studied for its potential role in:
Alpha-synuclein dynamics: May influence [alpha-synuclein](/proteins/alpha-synuclein) aggregation and clearance
Mitochondrial function: FAM172A localizes to mitochondria in [neurons](/entities/neurons) and may affect mitochondrial quality control
Lysosomal function: Possible involvement in lysosomal pathways relevant to PD pathogenesis
Cellular Mechanisms
FAM172A appears to affect neuronal survival through several mechanisms:
Protein quality control: May play a role in the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) and [autophagy](/entities/autophagy)
Cellular stress response: Involved in responses to oxidative stress and ER stress
Calcium homeostasis: Some studies suggest FAM172A affects calcium signaling in neurons
[Apoptosis](/entities/apoptosis) regulation: May modulate pro-apoptotic and anti-apoptotic pathways
Therapeutic Potential
Biomarker Potential
FAM172A has been investigated as a potential biomarker for neurodegenerative diseases:
Cerebrospinal fluid (CSF) levels: Altered FAM172A levels have been reported in AD and PD patients
Blood-based markers: Peripheral blood mononuclear cell expression changes have been observed
Drug Target Considerations
While FAM172A is not currently a validated drug target, several approaches could be explored:
Small molecule modulators: Compounds that enhance or inhibit FAM172A function
FAM172A remains a relatively understudied protein, presenting challenges for drug development:
Limited functional characterization: The normal physiological roles of FAM172A are not fully understood
Unknown structure: Crystal structure determination would aid drug design
Conflicting findings: Some genetic association studies have not replicated
See Also
Alzheimer's Disease Genetic Risk Factors
Parkinson's Disease Genetic Risk Factors
Protein Quality Control in Neurodegeneration
[Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
References
[Lambert JC, et al., Genome-wide association study identifies variants at CLU and CR1. Nat Genet. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19609660/)
[Naj AC, et al., Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21460841/)
[Chang D, et al., A meta-analysis of genome-wide association studies identifies novel loci for Parkinson's disease. Nat Genet. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/27992416/)
[Liu G, et al., FAM172A: A potential therapeutic target for neurodegenerative diseases. J Mol Neurosci. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32060671/)